Evidence map›Paper›PMID 37024306›Full record

ReviewAJNR. American journal of neuroradiology2023

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations.

C A P F Alves, A Zandifar, J T Peterson, S Z Tara, R Ganetzky, A N Viaene, S Andronikou, M J Falk, A Vossough, A C Goldstein

Open access · hybridAbstract readCase ReportsReview
In one paragraph

Review in AJNR. American journal of neuroradiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. MERRF/MELAS overlap syndrome mimicking paradoxical cerebral embolism due to patent foramen ovale.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  3. Article
  4. Sleep in MELAS syndrome.Sleep & breathing = Schlaf & Atmung · 2026
    Article
  5. Review
  6. Review
  7. Advances in Management of Mitochondrial Myopathies.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Phenotypic diversity in NAXE mutations.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  10. Review
  11. Neonatal and Syndromic Forms of Diabetes.Current diabetes reports · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Reply.AJNR. American journal of neuroradiology · 2024
    Article
  20. Advancing the neuroimaging diagnosis and understanding of mitochondrial disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

C A P F AlvesFrom the Division of Neuroradiology (C.A.P.F.A., A.Z., S.A., A.V.), Department of Radiology alvesc@chop.edu.ORCID 0000-0001-5877-9086
A ZandifarFrom the Division of Neuroradiology (C.A.P.F.A., A.Z., S.A., A.V.), Department of Radiology.ORCID 0000-0001-9480-949X
J T PetersonMitochondrial Medicine Frontier Program (J.T.P., S.Z.T., R.G., M.J.F., A.C.G.), Division of Human Genetics, Department of Pediatrics.ORCID 0000-0002-0480-5709
S Z TaraMitochondrial Medicine Frontier Program (J.T.P., S.Z.T., R.G., M.J.F., A.C.G.), Division of Human Genetics, Department of Pediatrics.ORCID 0000-0003-1199-5499
R GanetzkyMitochondrial Medicine Frontier Program (J.T.P., S.Z.T., R.G., M.J.F., A.C.G.), Division of Human Genetics, Department of Pediatrics.ORCID 0000-0001-6238-8109
A N ViaeneDepartment of Pathology and Laboratory Medicine (A.N.V.), The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0001-6430-8360
S AndronikouFrom the Division of Neuroradiology (C.A.P.F.A., A.Z., S.A., A.V.), Department of Radiology.ORCID 0000-0002-1015-9790
M J FalkMitochondrial Medicine Frontier Program (J.T.P., S.Z.T., R.G., M.J.F., A.C.G.), Division of Human Genetics, Department of Pediatrics.ORCID 0000-0002-1723-6728
A VossoughFrom the Division of Neuroradiology (C.A.P.F.A., A.Z., S.A., A.V.), Department of Radiology.ORCID 0000-0003-1346-427X
A C GoldsteinMitochondrial Medicine Frontier Program (J.T.P., S.Z.T., R.G., M.J.F., A.C.G.), Division of Human Genetics, Department of Pediatrics.ORCID 0000-0001-6593-5905
Anna Needs Neuroblastoma Answers · USDr. M.G.R. Educational and Research Institute · INMRC Mitochondrial Biology Unit · GBChildren's Hospital of Philadelphia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeAn increased number of pathogenic variants have been described in mitochondrial encephalomyopathy lactic acidosis and strokelike episodes (MELAS). Different imaging presentations have emerged in parallel with a growing recognition of clinical and outcome variability, which pose a diagnostic challenge to neurologists and radiologists and may impact an individual patient's response to therapeutic interventions. By evaluating clinical, neuroimaging, laboratory, and genetic findings, we sought to improve our understanding of the sources of potential phenotype variability in patients with MELAS. MATERIALS AND

methodsThis retrospective single-center study included individuals who had confirmed mitochondrial DNA pathogenic variants and a diagnosis of MELAS and whose data were reviewed from January 2000 through November 2021. The approach included a review of clinical, neuroimaging, laboratory, and genetic data, followed by an unsupervised hierarchical cluster analysis looking for sources of phenotype variability in MELAS. Subsequently, experts identified "victory-variables" that best differentiated MELAS cohort clusters.

resultsThirty-five patients with a diagnosis of mitochondrial DNA-based MELAS (median age, 12 years; interquartile range, 7-24 years; 24 female) were eligible for this study. Fifty-three discrete variables were evaluated by an unsupervised cluster analysis, which revealed that two distinct phenotypes exist among patients with MELAS. After experts reviewed the variables, they selected 8 victory-variables with the greatest impact in determining the MELAS subgroups: developmental delay, sensorineural hearing loss, vision loss in the first strokelike episode, Leigh syndrome overlap, age at the first strokelike episode, cortical lesion size, regional brain distribution of lesions, and genetic groups. Ultimately, 2-step differentiating criteria were defined to classify atypical MELAS.

conclusionsWe identified 2 distinct patterns of MELAS: classic MELAS and atypical MELAS. Recognizing different patterns in MELAS presentations will enable clinical and research care teams to better understand the natural history and prognosis of MELAS and identify the best candidates for specific therapeutic interventions.

Indexed as

Acidosis, LacticMELAS SyndromeStrokeDNA, MitochondrialFemaleHumansPhenotypeRetrospective StudiesDNA, Mitochondrial

Identifiers

PMID37024306
PMCPMC10171385
OpenAlexW4362660289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.